AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21684088 — intervention group
Group type: EXPERIMENTAL
Intervention: High problem severity subgroups
Number of subjects: 109
Study 18295859 — intervention group
Group type: EXPERIMENTAL
Intervention: ZITI‐2000
Number of subjects: 24
Study 18295859 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAT 2
Number of subjects: 24
Study 17386281 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser flap creation
Number of subjects: 1
Study 17386281 — intervention group
Group type: COMPARATOR
Intervention: Mechanical microkeratome (not separated due to complication)
Number of subjects: 1
Study 16642421 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected alendronate 70 mg/day
Number of subjects: 78
Study 16642421 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard alendronate 70 mg/day
Number of subjects: 78
Study 16642421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 14639802 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 and n‐6 LCP‐enriched formula (A)
Number of subjects: 31
Study 14639802 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (B)
Number of subjects: 31
Study 14639802 — intervention group
Group type: COMPARATOR
Intervention: Breast milk (control group)
Number of subjects: 31
Study 10073783 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of quinapril
Number of subjects: 1750
Study 10073783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1750
Study 7554971 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol (EE) + 150 micrograms desogestrel (group A)
Number of subjects: 65
Study 7554971 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinylestradiol (EE) + 250 micrograms norgestimate (group B)
Number of subjects: 65
Study 2109002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) at 4 ng/kg/min
Number of subjects: 8
Study 2109002 — intervention group
Group type: COMPARATOR
Intervention: Diluent (glycine buffer)
Number of subjects: 8
Study 2109002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 8
Study 6160322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg IV)
Number of subjects: 6
Study 6160322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg IV)
Number of subjects: 6
Study 31889358 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-Rollercoaster
Number of subjects: 136
Study 31889358 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-Ocean Rift
Number of subjects: 136
Study 31889358 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 30015735 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery with intended manual condylar positioning
Number of subjects: 18
Study 27624287 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months clopidogrel
Number of subjects: 1601
Study 27624287 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months clopidogrel
Number of subjects: 1601
Study 24329913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/day
Number of subjects: 35
Study 24329913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22095209 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized complex movement training (track group)
Number of subjects: 16
Study 22095209 — intervention group
Group type: COMPARATOR
Intervention: Simple movement training (move group)
Number of subjects: 16
Study 20696070 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based, tailored safety information combined with personal counselling
Number of subjects: 0
Study 20696070 — intervention group
Group type: COMPARATOR
Intervention: personal counselling using the Safety Information Leaflets
Number of subjects: 0
Study 18797697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg a day, orally)
Number of subjects: 60
Study 18797697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15736995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study 12432338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 62
Study 12432338 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day tamoxifen (n=16)
Number of subjects: 62
Study 12432338 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day tamoxifen (n=16)
Number of subjects: 62
Study 12432338 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day tamoxifen (n=15)
Number of subjects: 62
Study 10525131 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis (LA) combined with simvastatin 40 mg per day
Number of subjects: 12
Study 10525131 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis (LA)
Number of subjects: 12
Study 8624230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating/rotating brush (Braun Oral‐B Plaque Remover)
Number of subjects: 24
Study 8624230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Sonicare)
Number of subjects: 24
Study 8624230 — intervention group
Group type: COMPARATOR
Intervention: Manual brush (Crest Complete)
Number of subjects: 24
Study 2373273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 6
Study 2373273 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 6
Study 2373273 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 6
Study 7400475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline solution
Number of subjects: 16
Study 7400475 — intervention group
Group type: COMPARATOR
Intervention: Rectal theophylline solution
Number of subjects: 16
Study 31067489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training
Number of subjects: 0
Study 31067489 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for stimulus exposure)
Number of subjects: 0
Study 31067489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training (aMCI patients and healthy controls)
Number of subjects: 0
Study 31067489 — intervention group
Group type: COMPARATOR
Intervention: Control group (exposure condition)
Number of subjects: 0
Study 30088266 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain™ laryngeal mask
Number of subjects: 44
Study 30088266 — intervention group
Group type: COMPARATOR
Intervention: i-gel™ laryngeal mask
Number of subjects: 44
Study 26842543 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasive with glycine powder (AAD)
Number of subjects: 46
Study 26842543 — intervention group
Group type: COMPARATOR
Intervention: Manual debridement and chlorhexidine (MDA)
Number of subjects: 46
Study 24969812 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training
Number of subjects: 13
Study 24969812 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 13
Study 23506128 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 1860
Study 23506128 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (50 mcg every 4 hours)
Number of subjects: 1860
Study 21254008 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective laparoscopic cholecystectomy with on-table cholangiography (OTC)
Number of subjects: 190
Study 21254008 — intervention group
Group type: COMPARATOR
Intervention: Elective laparoscopic cholecystectomy alone
Number of subjects: 190
Study 21254008 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective laparoscopic cholecystectomy with OTC
Number of subjects: 190
Study 19668097 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy (OBVAT)
Number of subjects: 79
Study 19668097 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pencil push-ups (HBPP)
Number of subjects: 79
Study 19668097 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+)
Number of subjects: 79
Study 19668097 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy (OBPT)
Number of subjects: 79
Study 17902524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 micrograms every 4-6 hours, max six doses)
Number of subjects: 310
Study 17902524 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (50 micrograms every 4-6 hours, max six doses)
Number of subjects: 310
Study 17902524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 310
Study 17902524 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 310
Study 15316570 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) of 0.04
Number of subjects: 0
Study 15316570 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration (BAC) of 0.08
Number of subjects: 0
Study 15316570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10695818 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular irradiation after positive biopsy results
Number of subjects: 199
Study 10695818 — intervention group
Group type: COMPARATOR
Intervention: Negative biopsy results (no testicular irradiation)
Number of subjects: 199
Study 9235216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phenibut (0.25 g) with obsidan (0.08 g)
Number of subjects: 0
Study 9235216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9235216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemethyl (0.5 g)
Number of subjects: 0
Study 9235216 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenibut (0.25 g)
Number of subjects: 0
Study 9235216 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsidian (0.08 g)
Number of subjects: 0
Study 8444102 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrin (three doses of 500 mg)
Number of subjects: 96
Study 8444102 — intervention group
Group type: COMPARATOR
Intervention: Halofantrin (one-day therapy)
Number of subjects: 96
Study 8444102 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrin
Number of subjects: 96
Study 3028964 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable antimicrobial drugs (polymyxin and neomycin)
Number of subjects: 100
Study 3028964 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin and co-trimoxazole
Number of subjects: 100
Study 31164006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 270
Study 31164006 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-resistant schizophrenia
Number of subjects: 270
Study 31164006 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode psychosis
Number of subjects: 270
Study 31164006 — intervention group
Group type: COMPARATOR
Intervention: Healthy control groups
Number of subjects: 270
Study 30425195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 218
Study 30425195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 218
Study 30425195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 30425195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg or 10 mg BID)
Number of subjects: 218
Study 30425195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 218
Study 27580103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilmicosin (20 mg/kg, SC) once at dry off
Number of subjects: 172
Study 27580103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilmicosin (20 mg/kg, SC) twice (once at dry off and again 20 days later)
Number of subjects: 172
Study 27580103 — intervention group
Group type: COMPARATOR
Intervention: Ceftiofur (500 mg/mammary gland) at dry off
Number of subjects: 172
Study 24885729 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Healthy Lifestyle plus Family Recreation service integration (Comprehensive)
Number of subjects: 1168
Study 24885729 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Healthy Lifestyle service integration
Number of subjects: 1168
Study 24885729 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Recreation service integration
Number of subjects: 1168
Study 24885729 — intervention group
Group type: COMPARATOR
Intervention: Existing services
Number of subjects: 1168
Study 22545565 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time biofeedback
Number of subjects: 0
Study 22545565 — intervention group
Group type: COMPARATOR
Intervention: Sham biofeedback
Number of subjects: 0
Study 22545565 — intervention group
Group type: COMPARATOR
Intervention: Comparison of DPD patients and healthy volunteers
Number of subjects: 0
Study 21279932 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Atorvastatin daily for 6 months
Number of subjects: 52
Study 21279932 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Atorvastatin daily for 6 months
Number of subjects: 52
Study 21279932 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Atorvastatin daily for 6 months
Number of subjects: 52
Study 21279932 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin therapy
Number of subjects: 52
Study 18359821 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) therapy with physical therapy
Number of subjects: 40
Study 18359821 — intervention group
Group type: COMPARATOR
Intervention: Standard nonoperative physical therapy
Number of subjects: 40
Study 18359821 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) therapy
Number of subjects: 40
Study 18359821 — intervention group
Group type: COMPARATOR
Intervention: Standard nonoperative therapy
Number of subjects: 40
Study 16238586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dpt specific immunotherapy (IT)
Number of subjects: 60
Study 12030918 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 + TRH + GnRH infusion
Number of subjects: 33
Study 12030918 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 + TRH infusion
Number of subjects: 33
Study 12030918 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 infusion
Number of subjects: 33
Study 12030918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 12030918 — intervention group
Group type: COMPARATOR
Intervention: GHRP-2 alone
Number of subjects: 33
Study 10720964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low animal protein diet (< 10% of total energy)
Number of subjects: 96
Study 10720964 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet (> 25 g/day)
Number of subjects: 96
Study 10720964 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 96
Study 18476119 — intervention group
Group type: EXPERIMENTAL
Intervention: Butoconazole nitrate 2% cream for 3 days
Number of subjects: 398
Study 18476119 — intervention group
Group type: COMPARATOR
Intervention: Miconazole nitrate 2% cream for 7 days
Number of subjects: 398
Study 1593018 — intervention group
Group type: EXPERIMENTAL
Intervention: Human alpha leukocyte interferon (IFN) 50,000 IU, 1 ml, twice a week for 4-6 weeks
Number of subjects: 20
Study 1593018 — intervention group
Group type: EXPERIMENTAL
Intervention: Human alpha leukocyte interferon (IFN) 50,000 IU, 1 ml, twice a week for 4-6 weeks + IL-2
Number of subjects: 20
Study 1593018 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninjected nodule)
Number of subjects: 20
Study 4041688 — intervention group
Group type: EXPERIMENTAL
Intervention: Family management based on behavioural family therapy
Number of subjects: 36
Study 4041688 — intervention group
Group type: COMPARATOR
Intervention: Patient oriented management with family support
Number of subjects: 36
Study 31927716 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 980 (KANJINTI™)
Number of subjects: 725
Study 31927716 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab RP (Herceptin®)
Number of subjects: 725
Study 31927716 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab RP switched to ABP 980
Number of subjects: 725
Study 31409126 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO intervention (n=21), exposed to PARO over a period of two weeks, three times per week
Number of subjects: 39
Study 31409126 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18), read to aloud
Number of subjects: 39
Study 28538111 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotide targeting ANGPTL3 mRNA (single dose: 20, 40, or 80 mg; multiple doses: 10, 20, 40, or 60 mg per week for 6 weeks)
Number of subjects: 44
Study 28538111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25320185 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 0.2 to 2.0 g · kg(‐1) · d(‐1)
Number of subjects: 12
Study 25320185 — intervention group
Group type: COMPARATOR
Intervention: Current EAR and RDA based on nitrogen balance data
Number of subjects: 12
Study 23438709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 96
Study 23438709 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 96
Study 20729765 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (80 mg daily for 4 months)
Number of subjects: 38
Study 20729765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 4 months)
Number of subjects: 38
Study 20729765 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones
Number of subjects: 38
Study 20729765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19482863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IFNbeta-1a) 30 mug once weekly
Number of subjects: 0
Study 16549833 — intervention group
Group type: EXPERIMENTAL
Intervention: COL-3 (50 mg/d)
Number of subjects: 75
Study 16549833 — intervention group
Group type: EXPERIMENTAL
Intervention: COL-3 (100 mg/d)
Number of subjects: 75
Study 16549833 — intervention group
Group type: EXPERIMENTAL
Intervention: COL-3 (50 mg/d and 100 mg/d)
Number of subjects: 75
Study 16549833 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study 12637625 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus an optimized background regimen of three to five antiretroviral drugs
Number of subjects: 501
Study 12637625 — intervention group
Group type: COMPARATOR
Intervention: Optimized background regimen alone (control group)
Number of subjects: 501
Study 11378851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 0
Study 11378851 — intervention group
Group type: EXPERIMENTAL
Intervention: Short variant of the 5-HT transporter promoter polymorphism
Number of subjects: 0
Study 11378851 — intervention group
Group type: COMPARATOR
Intervention: 5-HT transporter promoter polymorphisms
Number of subjects: 0
Study 9232087 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 200 micrograms/q.i.d.
Number of subjects: 33
Study 9232087 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 micrograms/q.i.d.
Number of subjects: 33
Study 9232087 — intervention group
Group type: COMPARATOR
Intervention: Control group (not requiring steroids)
Number of subjects: 33
Study 7953987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements using the Lunar Achilles system
Number of subjects: 0
Study 3302053 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of ivermectin/kg
Number of subjects: 200
Study 3302053 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms of ivermectin/kg
Number of subjects: 200
Study 3302053 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of ivermectin/kg
Number of subjects: 200
Study 3302053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 2676174 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 12
Study 2676174 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 31754063 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with both biological parents
Number of subjects: 3907
Study 31754063 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher family life satisfaction
Number of subjects: 3907
Study 31699109 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal tDCS (c-TDCS)
Number of subjects: 13
Study 31699109 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 13
Study 31699109 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS (a-TDCS)
Number of subjects: 13
Study 31699109 — intervention group
Group type: COMPARATOR
Intervention: gait initiation and backward balance perturbation
Number of subjects: 13
Study 28763408 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-family conflict intervention
Number of subjects: 0
Study 26023227 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Citrulline (6 g/day)
Number of subjects: 10
Study 26023227 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Arginine (6 g/day)
Number of subjects: 10
Study 26023227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23473847 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically driven monitoring
Number of subjects: 1206
Study 23473847 — intervention group
Group type: COMPARATOR
Intervention: Routine laboratory monitoring
Number of subjects: 1206
Study 23473847 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug ART (NNRTI, lamivudine, abacavir)
Number of subjects: 1206
Study 23473847 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug ART (NNRTI, lamivudine, abacavir, zidovudine)
Number of subjects: 1206
Study 22036246 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50/50 (TID group)
Number of subjects: 302
Study 22036246 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro mix 75/25 or biphasic insulin aspart 70/30 (BID group)
Number of subjects: 302
Study 17985194 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based exercise programme
Number of subjects: 41
Study 17985194 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Number of subjects: 41
Study 16846551 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 6743
Study 16846551 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 6743